Abstract:Objective:To investigate the clinical characteristics, biological functions and molecular mechanism of polo-like Kinase 4 (Plk4) in gliomas.Methods:We studied the transcriptome data of glioma samples and clinical data of glioma patients in the Cancer Genome Atlas (TCGA) database (689 cases) and the Chinese Glioma Genome Atlas (CGGA) database (693 cases), and transcriptome data of normal brain tissue specimens in the GTEx database (255 cases) were also included. The differences in the expression of Plk4 in glioma specimens and normal brain tissues and glioma specimens of different pathological grades were compared. Log-rank test was used to compare the differences in overall survival between patients with low Plk4 expression and high expression groups. We took human astrocytes, U87, LN229, U251 and A172 cell lines for related research. Small interfering RNA (siRNA) transfection method was used to knock down the expression of Plk4 in U87 and LN229 cells. Real-time fluorescent quantitative polymerase chain reaction was used to detect the expression of Plk4 mRNA. Western blotting was used to detect the expression of Plk4 protein. EdU experiment and Transwell experiment were used to observe the effect of Plk4 on the proliferation, migration and invasion of glioma cells. Twenty 4-week-old female BALB/c-nu nude mice were taken, and U87 cells were injected into the abdomen of mice to prepare glioma xenogeneic tumor-bearing models. The differences in tumor volume and weight were analyzed between the Plk4 knockdown treatment group (intratumor injection of siRNA-Plk4) and the control group (injection of non-sequence Plk4) after 21 d (7 times) of treatment. We took U87 cells with knocked down Plk4, and used proteomics and phosphorylation analysis to explore the molecular mechanism of Plk4's biological function in gliomas.Results:Compared with astrocytes, the expression level of PLk4 mRNA in U87, LN229, U251 and A172 glioma cells was higher. TCGA combined with GTEx database data analysis showed that the expression level of Plk4 mRNA in low-grade glioma and glioblastoma specimens was higher than that in normal brain tissue. Analysis of the samples in the CGGA database showed that the expression level of Plk4 mRNA increased with the increase of the WHO pathological grade. In both databases, the overall survival of patients with high expression of Plk4 was shorter than that of patients with low expression of Plk4. The EdU experiment showed that the EdU positive rate of U87 and LN229 cells that knocked down Plk4 expression was lower than that of nonsense sequence cells. Transwell experiments showed that U87 and LN 229 cells that knocked down Plk4 expression had lower number of gel penetration than nonsense sequence cells. In vivo results showed that the growth rate of subcutaneous tumor in nude mice with Plk4 knockdown was significantly reduced. The differences in the above data were statistically significant (all P<0.01 or 0.05). In proteomics analysis, a total of 428 differentially expressed proteins were identified. In the phosphorylation analysis, a total of 1 180 differentially expressed phosphorylated peptides were identified, corresponding to 728 phosphorylated proteins. Correlation analysis of the results of proteomics and phosphorylation revealed that there were 2 197 proteins associated with proteomics and phosphorylation, of which 66 were only changed at the protein level, only 590 changed at the phosphorylation level, and 25 changed at both protein and phosphorylation levels. The GO function annotation and KEGG pathway enrichment analysis of 590 proteins with only changes at phosphorylation level found that the functions of 590 proteins were mainly protein binding and cadherin binding, etc. The main enrichment pathways were neurotrophic protein signaling pathway and long-term enhancement, etc. Conclusions:Plk4 is highly expressed in brain gliomas, which may be related to the prognosis of patients. Its mechanism may be related to the promotion of the proliferation, migration and invasion of glioma cells through signal pathways such as neurotrophic signaling pathway. Plk4 may be a molecular marker for the diagnosis and prognosis of glioma and a potential target for drug therapy.

Study on the function and molecular mechanism of Plk4 in gliomas

Effect of kinase PLK4 on the proliferation of glioma cells in vitro

PLK4 Initiates Crosstalk Between Cell Cycle, Cell Proliferation and Macrophages Infiltration in Gliomas

PLK1 Expression in Gliomas and Its Correlation to Tumor Proliferative Activity and Prognosis

Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling

Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma

Polo‑like Kinase4 Promotes Tumorigenesis and Induces Resistance to Radiotherapy in Glioblastoma

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma

Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells

Inhibition of PLK4 might enhance the anti‐tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway

Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme

Phospholipid Phosphatase 4 as a Driver of Malignant Glioma and Pancreatic Adenocarcinoma

The Prognostic Values and Immune Characteristics of Polo-Like Kinases (plks) Family: A Pan-Cancer Multi-Omics Analysis

Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.

Lipoprotein Lipase and Phospholipid Transfer Protein Overexpression in Human Glioma Cells and Their Effect on Cell Growth, Apoptosis, and Migration

Comprehensive Analysis of Differentially Expressed Genes Associated with PLK1 in Bladder Cancer

Abstract 3482: Single-cell transcriptome analysis reveals that PLK4 signature genes are highly associated with cancer proliferation and hotspot mutations in non-small cell lung cancer (NSCLC)

Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion

MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway

Molecular Pathological Study on Expression of Prb and CDK4，MTS Gene Changes in Human Gliomas